Biogen is cutting ties with Aduhelm, the Alzheimer’s disease drug that won a landmark but controversial regulatory approval and then became a commercial flop. Development and commercialization of ...
Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. In patients who’ve been treated with Aduhelm for up to two and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback